Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Submits HPV Tests to FDA

NEW YORK (GenomeWeb News) – Third Wave Technologies said today that it has submitted to the US Food and Drug Administration applications for clearance of two molecular tests for human papillomavirus.
The Madison, Wis.-based firm submitted data from trials on its 14-type high-risk HPV and 16/18 genotyping tests. The submissions come after last month’s announcement that the clinical trials on the two tests met their primary endpoints.
Third Wave intends to have an instrument on the market next year for the HPV tests, it said in a statement.
Third Wave said the global HPV testing market is projected to be $250 million in 2008. But the firm, and Qiagen, which sells the only FDA-cleared molecular test for HPV, believe the market is highly underpenetrated and could be valued at around $1 billion.
The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.